CRISPR Therapeutics AG (CRSP) Total Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Liabilities across 12 years of filings, most recently posting $904.2 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 183.82% year-over-year to $904.2 million; the TTM figure through Jun 2026 stood at $904.2 million (up 183.82% YoY), while the FY2025 annual figure was $343.4 million, up 10.8% from the prior year.
• Total Liabilities came in at $904.2 million for Q2 2026 at CRISPR Therapeutics AG, down from $911.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $911.3 million in Q1 2026 to a low of $310.0 million in Q4 2024.
• Average Total Liabilities over 5 years is $414.5 million, with a median of $359.0 million recorded in 2023.
• Year-over-year, Total Liabilities retreated 11.86% in 2024 and soared 183.82% in 2026.
• Over 5 years, Total Liabilities stood at $367.6 million in 2022, then declined by 5.66% to $346.8 million in 2023, then fell by 10.62% to $310.0 million in 2024, then climbed by 10.8% to $343.4 million in 2025, then jumped by 163.29% to $904.2 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $904.2 million in Q2 2026, $911.3 million in Q1 2026, and $343.4 million in Q4 2025.